Amgen drug cuts small cell lung cancer death risk by 40%
June 2 (Reuters) - Amgen's (AMGN.O), opens new tab Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemo, according to interim data from a late-stage trial presented at a major medical meeting on Monday.
The Phase 3 trial of 509 patients showed that Imdelltra extended median overall survival by more than five months to 13.6 months, compared with 8.3 months for standard-of-care chemotherapy, the company said.
The median length of time patients lived without their disease worsening, a measure known as progression-free survival, was 4.2 months for the Imdelltra group and 3.7 months for patients who received chemotherapy.
Amgen said the trial results are intended to serve as confirmatory evidence to support last year's accelerated approval by the U.S. Food and Drug Administration of Imdelltra for patients with extensive stage small cell lung cancer whose disease worsened on or after platinum-based chemotherapy.
The findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago and published in The New England Journal of Medicine.
Most lung cancer cases are non-small cell, while up to 15% are the more aggressive small cell variety targeted by Imdelltra, according to the American Cancer Society.
The Amgen drug belongs to a class of treatments called bispecific antibodies designed to attach to a cancer cell and an immune cell, bringing them together so that the body's immune system can kill the cancer.
Amgen said 27% of trial patients treated with Imdelltra experienced serious side effects, including low white blood cell counts, compared with 62% of chemotherapy patients. Patients on Imdelltra reported improvements in cough and shortness of breath compared to the chemotherapy group.
Cytokine release syndrome, a potentially dangerous condition that occurs when the body's immune system responds over aggressively to infection or immunotherapy drugs, was primarily low-grade and manageable, Amgen said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
India's Vedanta says Trump's tariffs damaging, seeks import curbs
June 4 (Reuters) - Indian metals-to-oil conglomerate Vedanta ( opens new tab said on Wednesday that U.S. President Donald Trump's doubling of aluminium tariffs to 50% poses a threat to the Indian industry already struggling with surging imports. Trump's latest round of tariffs on aluminium and steel, which took effect on Wednesday, have unsettled the global markets. "The 50% tariff announced by Trump is damaging to the Indian aluminium industry, which is already under pressure from surging imports that threaten to create surplus and risk to domestic market access," a Vedanta spokesperson told Reuters. The miner, which is the country's largest aluminium producer, urged the Indian government to implement tariffs to protect against imports. "..There should be duty guard-rails for the aluminium industry as well which has so far invested more than $20 billion to set up the current domestic primary aluminium capacity," the spokesperson said. India's cumulative aluminum exports fell 19% to 2.24 million metric tons in the fiscal year ended March 2025, according to government data. Separately, the country's federal steel minister said earlier this week that the impact of Trump's steel tariffs would be minor on the local industry, as India, the world's second-largest crude steel producer, does not export to the U.S. in significant quantities. In April, India imposed a 12% temporary tariff on some steel imports, locally known as a safeguard duty, to curb a surge in cheap shipments primarily from China.
Reuters
an hour ago
- Reuters
LinkedIn CEO to take over Office, more AI duties in Microsoft executive shuffle
SAN FRANCISCO, June 4 (Reuters) - The CEO of LinkedIn will take additional responsibility for Microsoft's Office products, while an executive responsible for one of the company's leading business-to-business artificial intelligence products will start reporting to head of the company's Windows unit, according to a memo from Microsoft CEO Satya Nadella viewed by Reuters. Ryan Roslansky, who oversees the business-focused social network owned by Microsoft, will remain CEO of LinkedIn but also oversee products such as Word and Excel and also "Copilot," Microsoft's leading AI product, within the company's productivity software suite, the memo said. Roslansky will report to Rajesh Jha, who oversees Microsoft Windows and Teams, among other duties. The memo said existing Office leaders Sumit Chauhan and Gaurav Sareen will report to Jha as well. Also moving to report to Jha will be Charles Lamanna, who leads "Copilot" for business and industrial users, the memo said.
Reuters
2 hours ago
- Reuters
Mexico to announce 'measures' next week if no deal on US metals tariffs
June 4 (Reuters) - Mexico will announce measures next week if there is no agreement reached with the United States on the steel and aluminum tariffs announced, president Claudia Sheinbaum said Wednesday. She also called the U.S. announcement to raise the metals' tariffs to 50% from the 25% introduce in March an "unfair measure" during her morning conference, citing the free trade agreement Mexico and Canada share with the United Sates. Sheinbaum however said that Mexico's response would not be "an eye for an eye." "It is not a matter of revenge, or retaliation as they call it in English," she said. "It is a matter of protecting our jobs and our businesses." U.S. President Donald Trump had late on Tuesday signed an executive proclamation activating the tariffs starting Wednesday. The Trump administration also wants countries to provide their "best offers" to avoid other punishing import levies from taking effect in early July, according to a draft letter to negotiating partners seen by Reuters. Economy Minister Marcelo Ebrard is set to hold talks with high-level U.S. officials this week, Sheinbaum said.
